SciVision Biotech Inc. (TPE:1786)

SciVision Biotech Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	592.4	706.02	511.1	587.02	658.92	397.36
Short-Term Investments	49.9	99.9	233.9	30.71	36.92	15.94
Cash & Short-Term Investments	642.3	805.92	745	617.73	695.84	413.31
Cash Growth	-25.43%	8.18%	20.60%	-11.23%	68.36%	-3.51%
Accounts Receivable	138.82	172.94	95.18	90.34	78.37	67.9
Other Receivables	7.1	1.09	1.02	1.16	0.2	0.33
Receivables	145.92	174.02	96.21	91.49	78.56	68.23
Inventory	74.1	72.23	87.25	95.87	82.9	45.9
Prepaid Expenses	36.91	47.94	15.48	18.65	21.7	24.42
Other Current Assets	62.29	66.3	59.97	57.29	46.24	1.58
Total Current Assets	961.51	1,166	1,004	881.03	925.24	553.45
Property, Plant & Equipment	1,216	1,176	1,135	1,184	1,246	1,296
Other Intangible Assets	1.63	1.68	2.15	2.67	3.38	4.43
Long-Term Deferred Tax Assets	7.39	5.02	15.5	25.04	31.33	31.85
Other Long-Term Assets	7.47	5.01	3.22	5.23	56.48	5.22
Total Assets	2,194	2,354	2,160	2,098	2,262	1,891
Accounts Payable	10.19	13.27	6.75	14.02	5.46	17.11
Accrued Expenses	122.34	135.76	102.56	78.4	-	-
Short-Term Debt	1.51	-	-	-	-	-
Current Portion of Long-Term Debt	120.22	134.79	-	-	303.37	-
Current Portion of Leases	9.91	4.73	1.22	1.2	1.24	0.79
Current Income Taxes Payable	8.75	12.65	5.77	13.97	-	8.78
Current Unearned Revenue	6.87	2.68	7.02	0.7	1.71	7.3
Other Current Liabilities	59.34	33.19	21.69	19.79	113.86	87.63
Total Current Liabilities	339.13	337.07	144.99	128.08	425.64	121.61
Long-Term Debt	-	-	323.84	386.69	300	296.56
Long-Term Leases	106.68	84.72	22.85	24.1	28.48	23.74
Long-Term Deferred Tax Liabilities	0.49	4.35	0.03	0.05	-	-
Other Long-Term Liabilities	23.21	23.15	23.03	22.91	22.78	2
Total Liabilities	474.52	457.43	533.67	587.31	812.06	486.55
Common Stock	721.92	717.92	677.1	661.9	661.9	610.05
Additional Paid-In Capital	844.18	844.08	700.34	648.26	638.12	638.12
Retained Earnings	154.6	335.25	249.73	201.61	150.72	156.86
Comprehensive Income & Other	-0.97	-0.2	-0.66	-0.84	-0.86	-0.85
Shareholders' Equity	1,720	1,897	1,627	1,511	1,450	1,404
Total Liabilities & Equity	2,194	2,354	2,160	2,098	2,262	1,891
Total Debt	238.32	224.24	347.91	411.99	633.09	321.08
Net Cash (Debt)	403.98	581.69	397.09	205.74	62.75	92.23
Net Cash Growth	-36.05%	46.49%	93.01%	227.89%	-31.96%	-21.16%
Net Cash Per Share	5.37	7.81	5.19	2.76	0.88	1.31
Filing Date Shares Outstanding	72.19	71.79	67.71	66.19	66.19	66.19
Total Common Shares Outstanding	72.19	71.79	67.71	66.19	66.19	66.19
Working Capital	622.38	829.35	858.92	752.95	499.6	431.84
Book Value Per Share	23.82	26.42	24.02	22.83	21.90	21.21
Tangible Book Value	1,718	1,895	1,624	1,508	1,446	1,400
Tangible Book Value Per Share	23.80	26.40	23.99	22.79	21.85	21.15
Land	4.73	4.73	4.73	4.73	9.5	9.5
Buildings	694.11	687.72	686.59	686.32	688.54	184.24
Machinery	958.24	926.47	909.63	896.45	891.02	223.58
Construction In Progress	32.56	20.57	3.5	4.62	0.77	1,186

Source: S&P Global Market Intelligence. Standard template. Financial Sources.